期刊文献+

托吡酯在精神科的临床应用进展 被引量:2

原文传递
导出
摘要 目的:了解托吡酯在精神科的临床应用进展。方法:利用Medline和中国知网查询托吡酯在精神科的临床应用相关文献,并进行回顾与综述。结果:托吡酯目前广泛地应用于多种不同类型精神障碍疾病的治疗,如双相情感障碍、精神分裂症及分裂情感性障碍、进食障碍、物质依赖等,或单用或作为辅助用药,都取得了一定的临床疗效,而最引人关注的是其对部分精神科药物所致体重增加的逆转作用。结论:托吡酯在精神科的临床应用广泛,其不良反应较轻微且易耐受。
出处 《中国药房》 CAS CSCD 2012年第48期4593-4596,共4页 China Pharmacy
  • 相关文献

参考文献36

  • 1Calabrese JR, Keck PE Jr, McElroy SL, et al. A pilot st-udy of topiramate as monotherapy in the treatment ofacute mania[J]. J Clin Psychopharmacol. 2001, 21 (3):340.
  • 2Grunze HC, Normann C, Langosch J, et al. Antimanicefficacy of topiramate in 11 patients in an open trial withan on-off-on design[J]. J Clin Psychiatry t 2001,62 (6):464.
  • 3Bozikas VP,Petrikis P,Kourtis A,et al. Treatment ofacute mania with topiramate in hospitalized patients [J].Prog Neuropsychopharmacol Biol Psychiatry, 2002,26(6):1 203.
  • 4Kushner SF, Khan A, Lane R, et al. Topiramate monoth-erapy in the management of acute mania: results of fourdouble-blind placebo-controlled trials [J]. Bipolar Disord,2006,8(I):15.
  • 5钱敏才,孙菊水.托吡酯与卡马西平治疗躁狂发作的疗效比较[J].中国新药与临床杂志,2003,22(11):671-673. 被引量:2
  • 6陈振华,白雪光,王晓萍,章华,王高华,藏德馨.托吡酯治疗双相障碍躁狂发作的疗效及对患者体重的影响[J].中国神经精神疾病杂志,2002,28(3):231-232. 被引量:7
  • 7Kusumakar V,Yatham L, Kutcher S, et al. Preliminary,open-label study of topiramate in rapid-cycling bipolarwomen[J]. Eur Neuropsychopharmacol, 1999,9 (Suppl5):357.
  • 8McIntyre RS,Mancini DA,McCann S,et al. Topiramateversus bupropion SR when added to mood stabilizer thera-py for the depressive phase of bipolar disorder: a prelimi-nary single blind study [J]. Bipolar Disord,2002,4(3):207.
  • 9Hussain MZ,Chaudhry ZA, Zubaida A, et al. Topirama-te in treatment of refractory bipolar depression[J]. EurNeuropsychopharmacol, 2001,11( Suppl 3) : 199.
  • 10Marcotte D. Use of topiramate, a new anti-epileptic as amood stabiliser[J]. J Affect Disord, 1998,50(2/3) : 245.

二级参考文献54

共引文献28

同被引文献26

  • 1范肖冬 汪向东 等.ICD-10精神与行为障碍分类[M].北京:人民卫生出版社,1993,5..
  • 2张明园.精神评定量表手册.长沙:湖南科学技术出版社,2003.8:17-27
  • 3Nickel MK, Loew TH. Treatment of aggression with topiramate in male borderline patients, part II. 18- month follow-up. Eur Psychiatry, 2008, 23 ( 2 ) : 115-117.
  • 4Farinde A, The impact of topiramate ( Topamax) thera- py on the development of aggressive and/or agitated be- havior. J Pharm Pract, 2011, 24 (6): 568-570.
  • 5Varghese BS, Rajeev A, Norrish M, Khusaiby SB. Topiramate for anger control: A systematic review. Indi- an J Pharmacol, 2010, 42 (3) : 135-141.
  • 6Terburg D, Morgan B, van Honk J. The testosterone- cortisol ratio: A hormonal marker for proneness to social aggression. Int J Law Psychiatry, 2009, 32 ( 4 ) : 216-223.
  • 7Siever LJ. Neurobiology of aggression and violence. Am J Psychiatry, 2008, 165 (4) : 429-442.
  • 8Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvarinen S, Eronen M, Putkonen H, Takala P, Mehtonen OP, Puck M, Oksanen J, Koskelainen P, Joffe G, Aer J, Hallikainen T, Ryynanen OP, Tupala E. Topiramate add-on in treatment-resistant schizophre- nia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry, 2005, 66 ( 8 ) : 1012-1015.
  • 9Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. Adjuvant topiramate adminis- tration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neurophar- macol, 2003, 26 (4): 199-206.
  • 10Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizo- phrenic patients experiencing weight gain. Clin Neurop- harmacol, 2005, 28 (4): 169-175.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部